Clinical Trial Search

Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate — 52.7; 60.1; 62.7; 47.7 Percentage of Participants — p=0.3393

Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants

Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants

Primary: Percentage of Participants With Active CD at Day 1 — 45.3 percentage of participants

Primary: Number of Participants With Flare Up of Crohn's Disease Through Month 12 — 6; 4; 0 participants

Primary: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 — 144; 36 Participants — p=<0.0001

Primary: Change Lewis Score Index — -225 units on a scale

Primary: Remission After 8-week of Treatment — 17; 14 Participants — p=0.526

Primary: Percentage of Participants That Achieved Symptomatic Remission at Week 6 — 40; 46 Participants

Primary: Cost of Illness in Participants With Crohn's Disease — 6088.40; 6169.62; 5594.00; 5825.80 Euros

Primary: • Evaluate the Effectiveness of the PillCam COLON 2 Bowel Prep Regimen in Crohn's Disease Patients — 62; 79 percentage of participants

Primary: Mucosal Change in VCE (Video Capsule Endoscopy) Mucosal Scores and PGA (Physician Global Assessment) — -0.3; -382.9; -2.7 units on a scale — p=0.631

Primary: Per-subject Diagnostic Yield of the PillCam Platform With the CD Capsule Within the Terminal Ileum and Colon as Compared to the Ileocolonoscopy Diagnostic Yield Within…

Primary: Sustained Relapse-free Remission — 6; 5 Participants

Primary: Diagnostic Yield in Suspected Crohn's Patients (CE Prior to IC vs. IC and SBFT) — 97.3; 57.3 percentage of yield — p=<0.0001

Primary: Maintenance of Symptomatic Remission, Without Worsening of Any Existing Disease Activity During Study Period — -31.63; -27.57 score on a scale — p=0.469

Primary: Crohn's Disease Activity Index (CDAI) Response (Clinical Response or Remission) at Week 6 — 25.0; 43.3; 48.4 percentage of subjects

Primary: Number of Participants With Clinical Response at Week 6 — 31; 48; 45; 52 Participants — p=0.005

Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants

Primary: Number of Participants in Clinical Remission at Treatment Week 20. Clinical Remission Defined as Harvey Bradshaw Index (HBI) Score Less Than 5. — 492 Participants

Primary: F. Prausnitzii (FISH Analysis). — 4.53; 5.07; 6.19; 5.46 Relative FISH counts from total bacteria

Primary: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) — 9.0; 38.0 percentage of…

Primary: Number of Participants With Clinical Response 70 at Week 4 — 14; 13; 18; 16 participants

Primary: Number of Participants With Adverse Events (AEs) — 453; 147; 360; 96 participants

Primary: Dietary Recalls (Calorific Intake) — 1900.9; 2054.3 kcal

Primary: CDAI Clinical Response -100 at Week 8 — 19; 11 Participants

Primary: Mean Extent of Exposure - Duration in Days — 159.2 days

Primary: Percentage of Subjects Achieving a 70-point Decline in CDAI Scores (Crohn's Disease Activity Index) Scores; — 40; 88 percentage of pts — p=0.009

Primary: Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of This Study CDP870-034 (up to 84 Months) — 94.2 percentage of subjects

Primary: Accuracy of CE Versus IC Plus MRE for Detecting Active Crohn's Disease (CD), by Visualizing the Small Bowel and Colon in Subjects With Know CD and Mucosal Disease. — 94…